Nowak et al have shown that a heart muscle protein has the ability to replace its skeletal counterpart and ensure a long and healthy life in lab mice.
The findings will be published online on Monday, May 25, 2009 (www.jcb.org) and will appear in the June 1, 2009 print issue of the Journal of Cell Biology.
AdvertisementThe contraction machinery protein, actin, exists in different forms in the adult heart and skeletal muscles. The heart form, ACTC, is also the dominant form in skeletal muscle of the fetus. But during development, the skeletal form, ACTA1, increases in production and by birth has taken over. It is not clear why the switch occurs, or why it doesn't occur in the heart, but it happens in every higher vertebrate and, for that reason, has been considered vitally important.
Mutations to the ACTA1 gene cause a rare but serious myopathy. Most patients die within the first year of life and some are born almost completely paralyzed. Mice lacking ACTA1 die nine days after birth. Nowak et al. wondered if ACTC could compensate for a lack of ACTA1. The two proteins differ only slightly but, like the developmental switch in production, this difference is conserved across species. Many researchers therefore assumed such compensation would never work.
But it did. Nowak and colleagues crossed Acta1 mutant mice with transgenic mice that express human ACTC at high levels in skeletal muscle cells. The resulting mice didn't die at nine days. In fact, almost all of them (93.5%) survived more than three months, and some more than two years. The mice's locomotor performance was comparable with wild-type, as was their overall muscle strength (though individual muscle fibers were slightly weaker), and their endurance was actually higher—they ran faster and for longer.
This begs the question, Why do we even have ACTA1? Besides pondering that, Nowak and colleagues are also working out how to boost endogenous ACTC as a possible therapy for ACTA1-lacking patients.